Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BlackRock Health Sciences Trust II (BMEZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: BMEZ (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 6.23% | Avg. Invested days 61 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.46B USD | Price to earnings Ratio 68.67 | 1Y Target Price - |
Price to earnings Ratio 68.67 | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 12.58 - 16.75 | Updated Date 06/29/2025 |
52 Weeks Range 12.58 - 16.75 | Updated Date 06/29/2025 | ||
Dividends yield (FY) 14.07% | Basic EPS (TTM) 0.21 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE 68.67 | Forward PE - | Enterprise Value - | Price to Sales(TTM) 59.22 |
Enterprise Value - | Price to Sales(TTM) 59.22 | ||
Enterprise Value to Revenue 53.02 | Enterprise Value to EBITDA - | Shares Outstanding 101255000 | Shares Floating - |
Shares Outstanding 101255000 | Shares Floating - | ||
Percent Insiders - | Percent Institutions 35.87 |
Upturn AI SWOT
BlackRock Health Sciences Trust II
Company Overview
History and Background
BlackRock Health Sciences Trust II (BMEZ) is a closed-end fund managed by BlackRock. It was incepted on December 28, 2020, with the objective of providing current income and current gains, with a secondary objective of long-term capital appreciation. It focuses on the health sciences sector.
Core Business Areas
- Closed-End Fund: Investment in equity securities of companies that are engaged in the health sciences industry. This includes pharmaceuticals, biotechnology, medical devices, and healthcare services.
Leadership and Structure
The fund is managed by a team of investment professionals at BlackRock. The specific individuals are not publicly disclosed in readily accessible documentation, though it is managed as a team.
Top Products and Market Share
Key Offerings
- Investment Portfolio: BMEZ offers an actively managed portfolio focused on health sciences equities. It does not have a 'market share' in the traditional sense of a product. It competes with other actively managed health sciences funds. Competitors include Tekla Healthcare Opportunities Fund (THQ) and Columbia Seligman Premium Tech and Healthcare Fund (STK).
Market Dynamics
Industry Overview
The health sciences industry is characterized by innovation, regulation, and demographic trends. It includes pharmaceutical companies, biotech firms, medical device manufacturers, and healthcare providers. Growth is driven by aging populations, technological advancements, and increasing healthcare spending.
Positioning
BMEZ positions itself as an active manager seeking to identify attractive investment opportunities within the health sciences sector. Its competitive advantage lies in BlackRock's research capabilities and global network.
Total Addressable Market (TAM)
The total market value of the Health Sciences sector is multiple trillions of dollars globally. BMEZ is positioned to capture a small portion of that through its fund, relying on stock selection and sector trends.
Upturn SWOT Analysis
Strengths
- Experienced management team (BlackRock)
- Access to BlackRock's research resources
- Active management strategy
- Focus on a growth sector (health sciences)
Weaknesses
- High expense ratio compared to passive ETFs
- Reliance on manager skill
- Closed-end fund structure can lead to trading at a discount to NAV
- Concentration in a single sector
Opportunities
- Aging global population drives demand for healthcare services
- Technological advancements in healthcare
- Increased healthcare spending in emerging markets
- Potential for innovation in biotech and pharmaceuticals
Threats
- Regulatory changes in healthcare
- Patent expirations and generic competition
- Economic downturns impacting healthcare spending
- Competition from other health sciences funds and ETFs
Competitors and Market Share
Key Competitors
- THQ
- STK
Competitive Landscape
BMEZ competes with other health sciences-focused funds, both closed-end and ETFs. Its active management strategy and BlackRock's resources are potential advantages.
Growth Trajectory and Initiatives
Historical Growth: Growth depends on the performance of the underlying investments and the overall health sciences sector.
Future Projections: Future growth projections are not provided by BlackRock as such, projections depend on broader trends in the health sciences industry and fund manager performance.
Recent Initiatives: Recent initiatives would involve adjusting the portfolio based on sector outlook and individual company analysis.
Summary
BlackRock Health Sciences Trust II is a closed-end fund focused on the health sciences sector, managed by BlackRock. It aims to provide income and capital appreciation through active portfolio management. The fund faces competition from other sector-specific funds and relies on its management team's expertise. Regulatory changes and market volatility in the healthcare industry pose potential risks to the fund's performance. Long-term, BMEZ can capitalize on the aging population and advancements in healthcare and biotech to continue to grow the portfolio.
Peer Comparison
Sources and Disclaimers
Data Sources:
- BlackRock official website
- SEC filings
- Financial news sources (e.g., Bloomberg, Reuters)
- Yahoo Finance
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual circumstances and after consulting with a qualified financial advisor. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BlackRock Health Sciences Trust II
Exchange NYSE | Headquaters New York, NY, United States | ||
IPO Launch date 2020-01-29 | CEO - | ||
Sector Financial Services | Industry Asset Management | Full time employees - | Website |
Full time employees - | Website | ||
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.